Features of Human CD3+CD20+ T Cells-Reference-Cited by-同舟云学术

Features of Human CD3+CD20+ T Cells

Published:2016-07-13 Issue:4 Volume:197 Page:1111-1117
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Schuh Elisabeth,Berer Kerstin,Mulazzani Matthias^ORCID,Feil Katharina,Meinl Ingrid,Lahm Harald^ORCID,Krane Markus,Lange Rüdiger^ORCID,Pfannes Kristina,Subklewe Marion,Gürkov Robert,Bradl Monika^ORCID,Hohlfeld Reinhard,Kümpfel Tania,Meinl Edgar,Krumbholz Markus

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference33 articles.

1. Anti–B Cell Antibody Therapies for Inflammatory Rheumatic Diseases

2. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

3. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

4. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

5. B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and characterization of circulating and adipose tissue infiltrated CD20+ T cells from subjects with obesity that undergo bariatric surgery;Immunology Letters;2024-10

2. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11

3. Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset;Multiple Sclerosis and Related Disorders;2024-09

4. Current Knowledge about CD3+CD20+ T Cells in Patients with Multiple Sclerosis;International Journal of Molecular Sciences;2024-08-18

5. Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study;Multiple Sclerosis Journal;2024-08